On Tuesday, Shares of Biogen Inc (NASDAQ:BIIB), lost -3.26% to $256.04. The stock attained the volume of 4.30 million shares.
The first shipments of much-needed hemophilia therapy have started to arrive at treatment centers across the developing world Biogen (BIIB), Swedish Orphan Biovitrum AB (publ) (Sobi) (SOBI.ST) and the World Federation of Hemophilia (WFH) declared recently. These shipments are part of the largest humanitarian aid pledge of its kind to assist people with hemophilia in developing countries.
The donation will provide up to 500 million units of hemophilia therapy over five years to the WFH and represents a noteworthy contribution to the expansion of their Humanitarian Aid Program, a 20-year old initiative dedicated to providing treatment and care for people with hemophilia in the developing world. This initiative is the first phase of Biogen and Sobi’s ten-year commitment to produce 1 billion International Units (IUs) of hemophilia therapy for humanitarian use.
Hemophilia is a rare, chronic, inherited disorder in which the ability of a person’s blood to clot is impaired. The WFH donation program is designed to create a sustainable model for humanitarian aid that has the potential to improve hemophilia care in regions of the world where, due to limited access to diagnosis and treatment, people with severe hemophilia often do not survive to adulthood. This donation is intended to assist enable a predictable and sustainable supply of therapy to countries in need, and is the first time treatment clinics will receive product manufactured specifically for humanitarian use. The first recipient countries of the donation comprise Senegal, Kenya, Philippines, Dominican Republic, Uzbekistan, Jordan, Egypt, Morocco, Pakistan, El Salvador, Indonesia, Ghana, Myanmar, India, Sri Lanka and Nigeria.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
Shares of CVS Health Corp (NYSE:CVS), dropped -1.00% to $102.04, during its last trading session.
SilverScript Insurance Company, a CVS Health (CVS) company, declared the company’s new Medicare Prescription Drug Plan (PDP) options for 2016. Medicare beneficiaries can choose from two SilverScript plans that offer $0 deductibles, lower premiums than the 2015 SilverScript plans in many states and low co-pays for several frequently prescribed drugs. In addition, the 2016 SilverScript prescription drug insurance plans earned an overall 4-star rating from the Centers for Medicare and Medicaid Services (CMS) in part for their high quality, clinical outcomes and customer service.
SilverScript will provide two Part D plan options in 2016: SilverScript Choice and SilverScript Plus. SilverScript Choice offers comprehensive coverage with low premiums and co-pays, and SilverScript Plus provides additional coverage in the Coverage Gap (Donut Hole). The Plus plan is designed for people who take several medications on a regular basis and are likely to reach the Coverage Gap during the 2016 plan year.
Both SilverScript PDPs offered in 2016 will feature$0-deductible, low copays for many drugs and competitive premiums. In fact, SilverScript premiums in 30 states are lower than they were in 2015 with premiums in eight of those states below $20, and SilverScript Choice plans have the lowest PDP premium in four states. Members can access a convenient nationwide network comprising of a wide selection of pharmacies across the country counting many large national and regional chains, many independent, community-based pharmacies, and the CVS/caremark mail service pharmacy. Additionally, in 2016, SilverScript is introducing a new formulary to keep co-pays low for some frequently prescribed drugs.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments.
Finally, Southern Co (NYSE:SO), ended its last trade with -0.13% loss, and closed at $45.55.
Georgia Power declared that the company presented a rebate of $49,297 to Gulfstream Aerospace Corp. through Georgia Power’s Commercial Energy Efficiency program. Gulfstream earned the rebate by installing high-efficiency LED exit signs, occupancy sensors and fluorescent and LED lighting equipment at its Savannah facility over the last two years. These upgrades have resulted in a savings of about 1,280 megawatt hours to date in addition to an predictable future reduction in energy costs.
Gulfstream has been an active participant in the Georgia Power Commercial Energy Efficiency Rebate Program since the program’s inception in 2011.
Gulfstream is also placing an raised focus on energy efficiency by installing sub-meters on buildings at the company’s Savannah facility to measure energy usage before and after improvements are made.
Georgia Power is the largest partner of Southern Company (SO).
The Southern Company, together with its auxiliaries, operates as a public electric utility company. It is involved in the generation, transmission, and distribution of electricity through coal, nuclear, oil and gas, and hydro resources in the states of Alabama, Georgia, Florida, and Mississippi.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
